Business Context and Reporting Period
Company: StemCells, Inc. (Note: Input metadata referenced "Microbot Medical Inc." but the filing text identifies the registrant as StemCells, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2003
Business Overview: The Company is engaged in the research and development of human therapeutic products, specifically focusing on stem cell technology for neural and liver diseases. It has not commercialized any products and has incurred operating losses since inception. Revenue is derived primarily from government grants and licensing agreements.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2003 | Nine Months Ended Sep 30, 2003 |
|---|---|---|
| Total Revenue | $32,790 | $152,040 |
| Net Loss | $(2,429,283) | $(7,551,435) |
| Net Loss Applicable to Common Stockholders | $(2,599,251) | $(9,256,538) |
| Net Loss Per Share (Basic & Diluted) | $(0.08) | $(0.30) |
| Cash and Cash Equivalents (Sep 30, 2003) | $4,169,851 | |
| Net Cash Used in Operating Activities (9 Months) | $(6,556,084) | |
| Total Liabilities | $4,862,788 | |
| Redeemable Convertible Preferred Stock | $1,829,780 (2,000 shares outstanding) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue for the nine months ended September 30, 2003, decreased to $152,040 from $326,310 in the same period in 2002. This was primarily due to the conclusion of a grant from the NIH's Small Business Innovation Research (SBIR) office and the decision not to draw further funds from a National Institute of Diabetes & Digestive & Kidney Disorders grant.
- Operating Expenses: Research and development expenses decreased by approximately 18% ($1,001,000) year-over-year for the nine-month period, driven by a cost reduction program initiated in late 2002 and a lease amendment reducing rent expenses in California. General and administrative expenses decreased by 6% ($204,000) due to similar cost-cutting measures, partially offset by resumed depreciation on Rhode Island facilities previously classified as held for sale.
- Deemed Dividends: The Company recorded a significant deemed dividend of approximately $1,658,000 for the nine months ended September 30, 2003, compared to $960,003 in the prior year. This increase was largely due to a reduction in the conversion price of 3% Cumulative Convertible Preferred Stock in April 2003, which triggered a beneficial conversion feature adjustment.
- Financing Activity: The Company raised $6,810,396 in net proceeds from the issuance of common stock during the nine-month period, primarily from a May 2003 transaction with The Riverview Group, LLC.
Guidance, Outlook, and Risks
- Liquidity and Going Concern: Management states the Company has very limited liquidity and capital resources. While the May 2003 financing is expected to fund operations into 2004, the Company must obtain significant additional capital to sustain product development and clinical testing. The financial statements do not include adjustments for the possible future effects of uncertainty regarding the Company's ability to continue as a going concern.
- Facility Obligations: The Company remains obligated under leases for former facilities in Rhode Island (pilot manufacturing and laboratory). Net lease obligations for 2003 are approximately $1,000,000 after sublease income. Failure to sublease, assign, or sell these interests could materially adversely affect liquidity.
- Scientific Progress: Preclinical studies on human neural stem cells (hCNS-SC) for spinal cord injury and Batten Disease showed promising results in animal models. The Company received a new $342,000 grant from the NINDS in September 2003 to further this work.
- Market Risk: The Company faces potential delisting from the Nasdaq SmallCap Market if it fails to meet continued listing requirements, which could severely limit stock liquidity and trigger breaches of registration rights agreements.
Investor Verification Checklist
- Cash Runway: Verify if the $4.17 million cash balance is sufficient to fund operations through 2004 given the high burn rate and ongoing facility lease obligations.
- Preferred Stock Redemption: Confirm the status of the remaining 2,000 shares of 3% Cumulative Convertible Preferred Stock, which have a mandatory redemption date of December 4, 2003, and a face value of $2,000,000.
- Facility Disposal: Monitor progress on subleasing or selling the Rhode Island facilities to mitigate the ~$1 million annual net lease obligation.
- Equity Line Expiration: Note that the $30 million equity line with Sativum Investments Limited expires in December 2003; verify if the Company can utilize this facility given market volume restrictions.
- Grant Dependency: Assess the sustainability of revenue streams given the discontinuation of previous NIH grants and reliance on new, smaller grants.